Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals PIC

AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline

Fineline Cube Aug 28, 2026
Company Deals Medical Device PIC

TÜV Rheinland and United Imaging Sign Strategic Cooperation MoU to Accelerate Global Market Access for Medical Devices

Fineline Cube Aug 28, 2026
Company Drug PIC

Gilead’s Bixlenvo Wins FDA Approval as Smallest Once-Daily Single Tablet HIV Regimen

Fineline Cube Aug 28, 2026
Company Drug PIC

Roivant’s Lisraya Wins FDA Approval as First Targeted Therapy for Dermatomyositis

Fineline Cube Aug 28, 2026
Company PIC

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

Fineline Cube Aug 27, 2026
Company Deals PIC

AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline

Fineline Cube Aug 28, 2026
Company Drug

Fosun Pharma’s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma

Fineline Cube Aug 28, 2026
Company Deals

Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential

Fineline Cube Aug 28, 2026
Company Deals

Lee’s Pharmaceutical Secures Rights to Eyedetec’s Dry Eye Device in Asia-Pacific

Fineline Cube Jun 9, 2023

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) through its subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622)...

Company Drug

NMPA Approves Betta Pharmaceuticals’ Vorolanib for Second-Line RCC Treatment in Combination with Everolimus

Fineline Cube Jun 9, 2023

The National Medical Products Administration (NMPA) has granted approval for Betta Pharmaceuticals Co., Ltd’s (SHE:...

Company Drug

Zelgen Biopharmaceuticals’ ZGGS15 Earns FDA Approval for Advanced Solid Tumor Clinical Trial

Fineline Cube Jun 9, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...

Company Drug

CSPC Pharmaceutical’s CPO301 Receives Health Canada Approval for Phase I Study

Fineline Cube Jun 9, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received the green...

Company Deals R&D

Shanghai Fosun High Technology Partners with NICE for Joint Innovation Centers

Fineline Cube Jun 9, 2023

China-based conglomerate Shanghai Fosun High Technology (Group) Co., Ltd has entered into a partnership with...

Company Deals

Samyang Holdings Partners with Yxintent for Lafullen Dermal Filler in China

Fineline Cube Jun 9, 2023

South Korea-based Samyang Holdings Biopharm Group has secured a partnership with Hangzhou-based Yxintent, a specialist...

Deals

Sequoia Capital to Split into Three Units, Including Independent China and India/SEA Divisions

Fineline Cube Jun 8, 2023

US-based investment fund Sequoia Capital has declared plans to reorganize its business into three distinct...

Company Drug

Jacobio Pharma Gets Green Light for Phase I/IIa Study of PARP7 Inhibitor JAB-26766

Fineline Cube Jun 8, 2023

China-based Jacobio Pharma (HKG: 1167) has announced receiving approval in China to initiate a Phase...

Company

BioMarin Pharmaceutical to Discontinue Vimizim Import License in China

Fineline Cube Jun 8, 2023

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has announced its decision not to renew the Import Drug...

Company Drug

Vcanbio Receives NMPA Approval for VUM02 Stem Cell Therapy in Liver Failure and ARDS

Fineline Cube Jun 8, 2023

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced receiving clinical trial...

Company Drug

Dizal Pharmaceutical Presents Updates on Sunvozertinib and Golidocitinib at ASCO 2023

Fineline Cube Jun 8, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented updates on the clinical development of its...

Company Drug

Abbisko Therapeutics’ Pimicotinib Earns PRIME Status for TGCT from EMA

Fineline Cube Jun 8, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that its Category 1 drug...

Company Medical Device

NMPA Approves Shenzhen Core Medical’s Implantable Left Ventricular Assist System

Fineline Cube Jun 8, 2023

The National Medical Products Administration (NMPA) has issued market approval for the implantable left ventricular...

Company Deals

uBriGene Partners with Everlife Biomed to Advance iPSC Therapy Preparation

Fineline Cube Jun 8, 2023

China-based uBriGene, a leading cell and gene therapy contract development and manufacturing organization (CDMO), has...

Company

EpimAb Biotherapeutics Appoints Dr. Zhu Yonghong as Chief Medical Officer

Fineline Cube Jun 8, 2023

Shanghai-based biotech company EpimAb Biotherapeutics has announced the appointment of Dr. Zhu Yonghong to the...

Company Drug

CStone Pharmaceuticals and Servier Report Positive AGILE Study Results for Tibsovo at ASCO

Fineline Cube Jun 7, 2023

CStone Pharmaceuticals’ (HKG: 2616) French partner, Servier, has published the latest results of the global...

Company Drug

BioNTech’s DB-1303 ADC Shows Promising Results in Solid Tumor Phase I/IIa Trial

Fineline Cube Jun 7, 2023

Germany’s BioNTech (NASDAQ: BNTX) has released preliminary data from a Phase I/IIa trial for DB-1303,...

Company Drug

Gilead’s Kite Announces Breakthrough Phase III Results for Yescarta in r/r LBCL

Fineline Cube Jun 7, 2023

Gilead’s (NASDAQ: GILD) subsidiary Kite has published groundbreaking Phase III results for Yescarta (axicabtagene ciloleucel),...

Company Drug

ITabMed Ltd Receives NMPA IND Approval for A-337, a CD3-Activating BsAb Targeting EpCAM

Fineline Cube Jun 7, 2023

Shanghai-based biotech firm ITabMed Ltd has announced the receipt of Investigational New Drug (IND) approval...

Policy / Regulatory

China’s MOST Issues Updated HGR Rules Impacting Foreign Collaborations in Genetic Research

Fineline Cube Jun 7, 2023

China’s Ministry of Science and Technology (MOST) has issued the “Detailed Implementation Rules for the...

Posts pagination

1 … 564 565 566 … 713

Recent updates

  • Fosun Pharma’s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma
  • Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential
  • HutchMed’s Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
  • AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline
  • Livzon Pharmaceutical’s Lecankitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Fosun Pharma’s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma

Company Deals

Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential

Company Drug

HutchMed’s Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma

Company Deals PIC

AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.